## 10/049608 C13 Rec'd PCTAPTO 12 FEB 2002

						Page <u>1</u> of <u>1</u>
FORM PTO-1449			Attorney Docket:	Serial No.:		
			3828-4000US2 TBA			
			Applicant:			
			Cohava Gelber			
INFORM	ATION DISCLOSURE CI	IAHON	Filing Date:	Group Art Unit:		1
			Herewith (February 12, 2002)	TBA		
	-	U.S.	, PATENT DOCUMENTS			
Examiner		Publicati			Sub-	
Initial	Patent Number	Date	Name	Class	Class	Filing Date
		i .				
		-				
		<u> </u>				
		<del> </del>				·
		<del> </del>				
	<del> </del>	<del> </del>		.		† —
		<u></u>			_	
		<del>                                     </del>			<u></u>	<del> </del>
		<del> </del>				<del> </del>
		FORE	IGN PATENT DOCUMENTS	<u> </u>	<u> </u>	
	<del></del>	Publication		<u> </u>	Sub-	T
Examiner	Dodge A Niverbara	Publication	Country	Class	Class	Translation
Initial	Patent Number		WO	Class	Class	Yes No
SIC	88/03954	06/02/88	WO			Yes No
<b></b>	96/26964	09/06/96				Yes No
	94/05329	03/17/94	wo			
	96/40295	12/19/96	WO			Yes No
					<u> </u>	Yes No
•	OTHE	R DOCUMI	ENTS (Including Author, Title, I	Date, etc.)		
	Partington K.M. et	al.: "A No	vel Method Of Cell Separation Bas	sed On Dual Paramo	eter Immune	omagnetic Cell
Sn.			MUNOLOGICAL METHODS, NI		NCE PUBI	JISHERS
<u> </u>	B.V., AMSTERDAM; vol. 223, no. 2; 4 March 1999 pp. 195-205.					
1			py Of Multiple Myeloma With A I			
1			HM1.24" BLOOD, W.B. SAUND	DERS, PHILADELF	HIA, VA, I	JS; vol. 90,
	no. 8; 15 October	1997				
ا.	Tai Y -T et al.: "ls	solation And	d Characterization Of Human Mult	iple Myeloma Cell	Enriched Po	pulations"
<b>A</b> L			GICAL METHODS, NL, ELSEVI	ER SCIENCE PUB	LISHERS E	3.V.,
	AMSTERDAM; v	ol. 235, no.	1-2; February 2000; pp. 11-19,			
				<i>7</i> · •		
Examiner	11		Date Considered	コノノ	/	İ
	1			7/5/0	6	
Examiner EXAMINER:	Initial if reference considered, whethe		is in conformance with MPEP §609.	7/5/0	6	
	1	iformance and	n is in conformance with MPEP §609.	7/5/0	6	

M 30 DEC E	FORM PT	Ω-1449	Attorney Docket: 3828-4000US2	Serial N 10/049,	Io.: 608 CHOCH	UN C
	,		Applicant: Cohava Gelber		CE	, "5
THORMATION DISCLOSURE CITATION			Filing Date: September 16, 2002	Group /	Art Unit:	Ep 160
		U.S. PAT	ENT DOCUMENTS			20/200
Examiner	Patent	Publication				
Initial	Number	Date	Name	Class	Sub-Class	Filing Date
					ļ	
· <del>- ·</del> ·	<u> </u>	- <del></del>				
	<u> </u>	FOREIGN I	PATENT DOCUMENTS			
Examiner	Patent	Publication				
Initial	Number	Date	Country	Class	Sub-Class	Translatio
				<u> </u>		Ves N
						☐ Yes ☐ N
					<u> </u>	☐ Yes ☐ N
						Yes N
<del></del>						Yes N
						☐ Yes ☐ N
		ID DOCUMENTS (I. I. I.	Tal. Date Date	dia and Demans		
		R DOCUMENTS (Included al., 1977, "Immunoreactiviti				ibodias with
sh	Human Carcinon	na Cells, Grown <i>In Vitro</i> an	d in a Zenograft Model", <u>Int</u>	t. J. Cancer, 72:	119-127.	
0,0	0.341 1. 1.			l by Bi-Specific	Monoclonal A	ntibody
0,00	S. Miotti et al., I'	999 "Level of Anti-Mouse-	Antibody Response Induced sociated with Longer Surviv	val". Int. J. Cano	er. 84-62-68.	
	J. A. Francisco e	nn-Carcinoma Patients is As t al., 1997, "In Vivo Efficac	sociated with Longer Surviv	val", Int. J. Cand	er, 84-62-68. exin Targeted t	o CD40".
0,0	J. A. Francisco e Blood, 89:4493 C.F.M. Molthoff	an-Carcinoma Patients is As t al., 1997, "In Vivo Efficac 4500. et al., 1997, "Escalating Pro	sociated with Longer Surviv y and Toxicity of a Single-O otein Doses of Chimeric Mo	val", <u>Int. J. Cand</u> Chain Immunoto onoclonal Antibo	oxin Targeted to	
0,0	DC/TR in Ovaria J. A. Francisco e Blood. 89:4493 C.F.M. Molthoff G. In Ovarian Ca	nn-Carcinoma Patients is As t al., 1997, "In Vivo Efficac 4500. et al., 1997, "Escalating Pro ircinoma Patients: A Phase	sociated with Longer Surviv y and Toxicity of a Single-Cotein Doses of Chimeric Mo I Study", CANCER Supple	val", Int. J. Cano Chain Immunoto moclonal Antibo ment. 80:2712-	oxin Targeted to ody Mov18 Im 2720.	munoglobulii
	DC/TR in Ovaria J. A. Francisco e Blood, 89:4493 C.F.M. Molthoff G. In Ovarian Ca E. Kievit et al., 1 Antibody 323/A	an-Carcinoma Patients is As t al., 1997, "In Vivo Efficac 4500. Tet al., 1997, "Escalating Pro- arcinoma Patients: A Phase 997, "Determination of Tur 3 in Experimental Human O	sociated with Longer Surviv y and Toxicity of a Single-Contein Doses of Chimeric Mo I Study". CANCER Supplemor-Related Factors of Influvarian Cancer", Int. J. Canc	val", Int. J. Cano Chain Immunoto moclonal Antibo ment. 80:2712-2 ence on the Upt er, 71:237-245.	oxin Targeted to ody Mov18 Im 2720. ake of the Mor	munoglobuli noclonal
	DC/TR in Ovaria J. A. Francisco e Blood, 89:4493 C.F.M. Molthoff G. In Ovarian Ca E. Kievit et al., 1 Antibody 323/A K.O. Lloyd et al.	an-Carcinoma Patients is As t al., 1997, "In Vivo Efficac 4500. Fet al., 1997, "Escalating Pro- arcinoma Patients: A Phase 997, "Determination of Tur 3 in Experimental Human O , 1997, "Isolation and Chara	sociated with Longer Surviv y and Toxicity of a Single-Cotein Doses of Chimeric Mo I Study". <u>CANCER Supplemor-Related Factors of Influvarian Cancer</u> ", Int. J. Canceterization of Ovarian Cancer	val", Int. J. Cano Chain Immunoto onoclonal Antibo ment. 80:2712-2 ence on the Upt er, 71:237-245. cer Antigen CA	oxin Targeted to ody Mov18 Im 2720. ake of the Mor 125 using a Ne	munoglobulit noclonal
	DC/TR in Ovaria J. A. Francisco e Blood, 89:4493- C.F.M. Molthoff G. In Ovarian Ca E. Kievit et al., 1 Antibody 323/A K.O. Lloyd et al. Antibody (VK-8 A. van Dalen, 19	an-Carcinoma Patients is Astal., 1997, "In Vivo Efficace 4500." The Vivo Efficace 4500. The first and Patients: A Phase 1997, "Determination of Ture 3 in Experimental Human Opportunity, "Isolation and Chara"): Identification as a Mucin 199, "BR-MA, OM-MA, GI-	sociated with Longer Survivy and Toxicity of a Single-Cotein Doses of Chimeric Mol I Study". CANCER Supplemor-Related Factors of Influvarian Cancer", Int. J. Canceterization of Ovarian Cance-Type Molecule", Int. J. Canceterization of Cancer, Int. J. Canceterization of Ovarian Cancer	val", Int. J. Cano Chain Immunoto onoclonal Antibo ment. 80:2712-1 ence on the Upt er, 71:237-245. ter Antigen CA neer, 71:842-58	oxin Targeted to ody Mov18 Im 2720. ake of the Mor 125 using a Ne 0.	munoglobulir noclonal ew Monoclon
	DC/TR in Ovaria J. A. Francisco e Blood, 89:4493- C.F.M. Molthoff G. In Ovarian Ca E. Kievit et al., 1 Antibody 323/A K.O. Lloyd et al. Antibody (VK-8 A. van Dalen, 19 Tumore Biology G. Gebauer et al.	an-Carcinoma Patients is As t al., 1997, "In Vivo Efficac 4500. Tet al., 1997, "Escalating Pro- incinoma Patients: A Phase 997, "Determination of Tur 3 in Experimental Human O , 1997, "Isolation and Chara ): Identification as a Mucin 199, "BR-MA, OM-MA, GI- , 20:117-129. . 1999, "IMMULITIER OM	sociated with Longer Survivy and Toxicity of a Single-Cotein Doses of Chimeric Mol Study", CANCER Supplemor-Related Factors of Influvarian Cancer", Int. J. Canceterization of Ovarian Cance-Type Molecule", Int. J. Canceterization of Cancer Chimical Evaluation of Cancer Chimica	val", Int. J. Cane Chain Immunoto monclonal Antibe ment. 80:2712 ence on the Upt er, 71:237-245. Ser Antigen CA neer. 71:842-58 aluation Using t	oxin Targeted to ody Mov18 Im 2720. ake of the Mou 125 using a Ne 0. he IMMULITE	munoglobulín noclonal ew Monoclon E Analyzer",
	DC/TR in Ovaria J. A. Francisco e Blood, 89:4493- C.F.M. Molthoff G. In Ovarian Ca E. Kievit et al., 1 Antibody 323/A K.O. Lloyd et al. Antibody (VK-8 A. van Dalen, 19 Tumore Biology G. Gebauer et al.	an-Carcinoma Patients is Ast al., 1997, "In Vivo Efficac 4500. Tet al., 1997, "Escalating Proceeding Patients: A Phase 997, "Determination of Tur 3 in Experimental Human O., 1997, "Isolation and Chara): Identification as a Mucin 199, "BR-MA, OM-MA, GI- 1, 20:117-129.	sociated with Longer Survivy and Toxicity of a Single-Cotein Doses of Chimeric Mol Study", CANCER Supplemor-Related Factors of Influvarian Cancer", Int. J. Canceterization of Ovarian Cance-Type Molecule", Int. J. Canceterization of Cancer Chimical Evaluation of Cancer Chimica	val", Int. J. Cane Chain Immunoto monclonal Antibe ment. 80:2712 ence on the Upt er, 71:237-245. Ser Antigen CA neer. 71:842-58 aluation Using t	oxin Targeted to ody Mov18 Im 2720. ake of the Mou 125 using a Ne 0. he IMMULITE	munoglobulir noclonal ew Monoclon E Analyzer".

## FORM PTO-1449

## INFORMATION DISCLOSURE CITATION

		Febra of 3
Attorney Docket: 3828-4000US2	Serial No.: 10/049,608	in the
Applicant: Cohava Gelber	CAC	EN 5 200
Filing Date: September 16, 2002	Group Art Unit: 1641	16P/60

JC6,	S.P. Treon et al., 1999, "Muc-1 Core Protein Is Expressed on Multiple Myeloma Cells and Is Induced by
/ Con it	Dexamethasone", Blood, 93:1287-1298.
Show	Ono et al., 1999, "The humanized anti-HM1.24 antibody effectively kills multiple myeolma cells by human
Show	effector cell-mediated cytotoxicity", Mol. Immunology, 36:387-395.
	Teoh et al., 1998, "The 86kD Subunit of Ku Autoantigen Mediates Homotypic and Heterotypic Adhesion of
wise,	Jultiple Myeloma Cells". J. Clin. Invest., 101:1379-1388.
	W.C.A.M. Buijs et al., 1998, "Dosimetric analysis of chimeric monoclonal antibody cMOv18 IgG in ovarian
Dilen's	carcinoma patients after intraperitoneal and intravenouse administration". Eur. J. Nuclear Medicine, 25:1552-1561.
STU	carcinoma patients after intrapertioneal and intravenouse administration. Fur. 5. Nuclear increasing Openious 25:381
CID	M.A. Bookman, 1998, "Biological Therapy of Ovarian Cancer: Current Directions:. Seminars in Oncology, 25:381-
SR_	396.
	M. Kawata et al., 1998, "Detection of Epithelial Ovarian-Cancer-Associated Antigens Involved in Immune
1	Complexes by Monoclonal Antibodies", Tumor Biology, 19:1-11.
	S.A. McQuarrie et al., 1997, "Pharmacokinetics and radiation dosimetry of "Fe"-labelled monoclonal antibody
1	B43.13 in ovarian cancer patients", Nuclear Medicine Communications, 18:878-886.
	F. Kievit et al., 1997, "Comparison of the Biodistribution and the Efficacy of Monoclonal Antibody 323/A3 Labeled
	with Either <sup>131</sup> I or <sup>186</sup> Re in Human Ovarian Cancer Xenografts", Int. J. Radiation Oncology bio. Phys., 38:813-832.
	M. Hartman et al., 1999, "MUCI Isoform Specific Monoclonal Antibody 6E6/2 Detects Preferential Expression of th
İ	Novel MUC1/Y Protein in Breast and Ovarian Cancer", Int. J. Cancer, 82-256-267.
	M.L. Grossbard et al., 1998 "Anti-B4-blocked ricin: a phase II trial of 7 day continuous infusion in patients with
1	multiple myeloma", British Journal of Haematology, 102:509-515.
	II Bertz et al., 1997, "Adoptive immunotherapy for relapsed multiple myeloma after allogeneic bone marrow
1	H Bertz et al., 1997, "Adoptive immunotherapy for relapsed multiple hydronia after a logicities of marrow
	transplantation (BMT): evidence for a graft-versus-myeloma effect", Leukemia, 11:281-283.
	J L. Hornick et al. 1997, "Chimeric CLL-1 antibody Fusion Proteins Containing Granulocyte-Macrophage Colony-
	Stimulating Factor or Interleukin-2 with Specificity for B-Cell Malignancies Exhibit Enhanced Effector functions
	while Retaining Tumor Targeting Properties", Blood, 89:4437-4447.
ı	D.G. Maloney et al., 1999, "Antibody Therapy for treatment of Multiple Myeloma". Seminars in Hematology
	(Suppl.), 36:30-33.
	V Nuessler et al., 1997, "Functional P-gp expression in multiple myeloma patients at primary diagnosis and relapse
1	or progressive disease"" Leukemia (Suppl.), 11:S10-S14.
	G.J. Ossenkoppele, 1997, "Treatment of Multiple Myeloma in Elderly Patients", Drugs & Aging, 11:152-164.
	T.H. Totterman et al., 1998, "Targeted Superantigens for Immunotherapy of Haematopoietic Tumors", Vox
1	Sanguinis, 74:483-487
	M.G. Rosenblum et al., 1999, "Phase I Study of 90Y-labeled B72.3 Intraperitoneal Administration in Patients with
1	Ovarian Cancer: Effect of Dose and EDTA Coadministration on Pharmacokinetics and Toxicity". Clinical Cancer
1	Research, 5:953-961.
	R.H. M. Verheijen et al., 1999, "CA 125: fundamental and clinical aspects", Seminars in Cancer Biology, 9:117-124
	G. Fleckenstein et al., 1998, "Monoclonal antibodies in solid tumours: approaches to therapy with emphasis on
1	
	gynaecological cancer", Medical Oncology, 15:212-221.
l	E. Kievit et al., 1998 "[186]-Labeled Mouse and Chimeric Monoclonal Antibody 323/A3: a Comparison of the
	Efficacy in Experimental Human Ovarian Cancer", Nuclear Medicine & Biology, 25:37-45.
1	S. Nicholson et al., 1998, "Radioimmunotherapy after chemotherapy compared to chemotherapy alone in the
	treatment of advanced ovarian cancer: A matched analysis", Oncology Reports, 5:223-226.
L	B.C. Schultes et al., 1998, "Anti-idiotype induction therapy: anti-CA125 antibodies (Ab <sub>3</sub> ) mediated tumor killing in
4/	patients treated with Ovarex mAb B43.13 (Ab <sub>1</sub> ). Cancer Immunol. Immunother, 46:201-212
-	

Examiner	1 4	Date Considered	7/5/06		
FXAMINER.	Initial if reference considered, whether or not citation is in conform	iance with MPFP 56697	, , , ,		
	Draw line through citation if not in conformance and not considered.				
	Include copy of this form with next communication to Applicant.				



## **FORM PTO-1449**

Attorney Docket:

3828-4000US2

Applicant:
Cohava Gelber

Filing Date:
September 16, 2002

Group Art Of National September 16, 2002

Figure 1641

Frage 3 6...

Frage 3 6.

RMATION DISCLOSURE CITATION

M. Jojovic et al., 1998, "Epithelial glycoprotein-2 expression is subject to regulatory processes in epithelial mesenchymal transitions during metastases: an investigation of human cancers transplanted into severe combined immunodeficient mice", Histochemical Journal, 30:723-729. C. Kosmas et al., 1998, "Monoclonal Antibody Targeting of Ovarian Carcinoma", Oncology, 55:435-446. M.F. Federici et al., 1999. "Selection of Carbohydrate Antigens in Human Epithelial Ovarian Cancers as Targets for Immunotherapy: Serous and Mucinous Tumors Exhibit Distinctive Patterns of Expression", Int. J. Cancer, 81:193-W.G. McCluggage et al., 1998, "Immunocytochemical staining of ovarian cyst aspirates with monoclonal antibody against inhibin", Cytopathology, 9:336-342. H.C.T. Van Zaanen et al., 1998, "Blocking Interleukin-6 Activity with Chimeric Anti-IL6 Monoclonal Antibodies in Multiple Myeloma: Effects on Soluble IL6 Receptor and Soluble gp 130", Leukemia and Lymphoma, 31:551-558. V.L. Reichardt et al., 1997, "Rationale for adjuvant idiotypic vaccination after high-dose therapy for multiple myeloma", Biol. Blood and Marrow Transplant, 3:157-163. N.L. Smith et al., 1999, "Immunohistochemically detecting target antigens in patient biopsies for tailoring monoclonal antibody based cancer therapy", human Antibodies, 9:61-65. E. Harlow et al., 1988, "Labeling Antibodies", Antibodies: A Laboratory Manual, pp. 321-631. N.S. Greenspan et al., 1999, "Defining epitopes: It's not as easy as it seems", Nature Biotechnology, 17:936-937. P. Knight, 1989, "The Carbohydrate Frontier", Biotechnology, 7:35-40. J.M. Cruse et al., 1995, Illustrated Dictionary of Immunology, p. 22. W. Paul, 1993, Fundamental Immunology, Raven Press, NY Chpt 8, p. 242.

Examiner	1	Date Considered	7/5/64		
FXAMINER.	Initial if reference considered, whether or not citation is in conform	guce with MPFP 3009			
:	Draw line through citation if not in conformance and not considered				
Ĺ	Include copy of this form with next communication to Applicant.				